PRIME: priority medicines
PRIME: priority medicines
PRIME: priority medicines
Call for expression of interest for independent scientific experts to participate in the work of EMA’s Safety Committee
Call for expressions of interest for patients’ organisations representatives to join Committee for Orphan Medicinal Products (COMP)
Scientific publications
Clinical requirements for non replacement therapy in haemophilia A and B - Scientific guideline
Influenza vaccines - non-clinical and clinical module - Scientific guideline
Concept paper on the revision of the Non-clinical and Clinical Module of the influenza vaccines guideline
Human medicines European public assessment report (EPAR): CoAprovel, irbesartan,hydrochlorothiazide, Hypertension, Date of authorisation: 14/10/1998, Revision: 49, Status: Authorised
Human medicines European public assessment report (EPAR): Champix, varenicline, Tobacco Use Cessation, Date of authorisation: 25/09/2006, Revision: 38, Status: Authorised
Human medicines European public assessment report (EPAR): Venclyxto, venetoclax, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 04/12/2016, Revision: 16, Status: Authorised